Thursday, December 1st, the Counselor Otto Malmgren at the Norwegian Embassy in Tokyo, gave opening remarks to Medistim’s symposium “The necessity of quality assessment in CABG” held at the 8th International Coronary Congress in Tokyo.
“This is very much a story of a perfect fit between Norwegian technology and Japanese quality standards. Medistim technology has been able to meet expectations of the quality driven Japanese market. There are few arenas in our societies where precision and reliable tools are as crucial as to the best outcome for the patients as in complex open-heart surgery, “ says Otto Malmgren.
The symposium is moderated by Dr. Hirokuni Arai, Professor Emeritus of Tokyo Medical and Dental University and President of Hokushin General Hospital in Nagano Japan. He is currently Society President of the Japanese Association for Coronary Artery Surgery (JACAS) and hosting the International Coronary Congress (ICC) 2022 in Tokyo.
“Medistim has a long history of working together with, and helping to connect, world leading surgeons to share clinical best practices, and our ongoing support to the International Coronary Congress is an excellent example,” says Medistim President and CEO, Kari E. Krogstad. “As this year’s ICC takes place in Tokyo, Japan, it provides a great opportunity for us to celebrate Medistims’ market leading position with more than 80 % of the Coronary Artery Bypass market in Japan, the highest share in the world outside our home-market Norway. It has been a privilege for Medistim to work closely with outstanding Japanese surgeons in our development of Medistim’s technology, providing the intraoperative surgical guidance and quality control needed in these complex open-heart procedures.”
“At Norway Health Tech, we have followed Medistim and the company’s venture into the Japanese market since 2018. We are proud and impressed by the solid breakthrough the company has achieved, and the market leadership position the company has managed to create within coronary bypass surgery. Norway has a goal of increasing exports from mainland industries by 50 percent by 2030. In that context, the health industry is crucial, because it is independent of the economic cycle, and because Norway has world-class health technology that can compete on the global market. Medistim is an excellent example of that, says CEO of Norway Health Tech, Lena Nymo Helli.”